Advertisement

Irish Journal of Medical Science (1971 -)

, Volume 186, Issue 3, pp 647–652 | Cite as

Radiotherapy for the treatment of thyroid eye disease—a prospective comparison: Is orbital radiotherapy a suitable alternative to steroids?

  • P. GrassiEmail author
  • D. Strianese
  • R. Piscopo
  • R. Pacelli
  • G. Bonavolontà
Original Article

Abstract

Background and aims

To evaluate the efficacy of orbital radiotherapy (OR) for the treatment of thyroid eye disease (TED).

Methods

Thirty-five consecutive patients with active TED with contraindications to steroid therapy received a course of OR. Bilateral retrobulbar irradiation was performed with a total dose of 20 Gy. 7-points clinical activity score (7-CAS), ocular motility, visual acuity (VA), exophthalmos and eyelid retraction were prospectively evaluated at 3, 6 and 12 months and compared with baseline data.

Results

There was a statistically significant improvement in 7-CAS at 3, 6 and 12 months post-treatment (p < 0.05). Ocular motility disturbances improved at 6 and 12 months (p < 0.05). Visual acuity remained stable; there was no significant change in exophthalmos (mean 24 mm, SD 3 mm) or eyelid retraction (marginal reflex distance mean 6 mm, SD 1.5 mm) during the follow-up period. No side effects were registered.

Conclusions

This study suggests that OR might be effective in reducing 7-CAS and ocular motility disturbances. No significant improvement in proptosis or eyelid retraction should be expected from this treatment. OR might be considered a suitable alternative treatment in TED for patients who cannot tolerate steroids.

Keywords

Alternative first-line therapy Graves ophthalmopathy Orbital radiotherapy Thyroid eye disease 

Notes

Compliance with ethical standards

No funding/financial support was received for this submission.

Conflict of interest

Dr. Piergiacomo Grassi MD declares that he has no conflict of interest. Dr. Diego Strianese MD Ph.D. declares that he has no conflict of interest. Dr. Raffaele Piscopo MD Ph.D. declares that he has no conflict of interest. Dr. Roberto Pacelli MD declares that he has no conflict of interest. Prof. Dr. Giulio Bonavolontà MD declares that he has no conflict of interest.

Ethical approval

All procedures performed in this study were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments.

Informed consent

It was obtained from all individual participants included in this study.

References

  1. 1.
    Bahn RS (2010) Graves’ ophthalmopathy. N Engl J Med 362(8):726–738CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Comerci M, Elefante A, Strianese D (2013) Semiautomatic regional segmentation to measure orbital fat volumes in thyroid-associated ophthalmopathy. A validation study. Neuroradiol J 26(4):373–379CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Abalkhail S, Doi SA, Al-Shoumer KA (2003) The use of corticosteroids versus other treatment for Graves ophthalmopathy: a quantitative evaluation. Med Sci Monit 9:477–483Google Scholar
  4. 4.
    Koshiyama H, Koh T, Fujiwara K et al (1994) Therapy of Graves ophthalmopathy with intravenous high-dose steroid followed by orbital irradiation. Thyroid 4:409–413CrossRefPubMedGoogle Scholar
  5. 5.
    Wiersinga WM, Prummel MF (2002) Graves ophthalmopathy: a rational approach to treatment. Trends Endocrinol Metab 13:280–287CrossRefPubMedGoogle Scholar
  6. 6.
    Bartalena L, Marcocci C, Tanda L et al (2002) Management of thyroid eye disease. Eur J Nucl Med Mol Imaging 29(Suppl 2):S458–S465CrossRefPubMedGoogle Scholar
  7. 7.
    Krassan GE, Heufelder AE (2001) Immunosuppressive therapy in patients with thyroid eye disease: an overview of current concepts. Eur J Endocrinol 144(4):311–318CrossRefGoogle Scholar
  8. 8.
    Marcocci C, Kahaly GJ, Krassas GE et al (2011) Selenium and the course of mild Graves’ orbitopathy. N Engl J Med 364(20):1920–1931CrossRefPubMedGoogle Scholar
  9. 9.
    Mourits MP, van Kempen-Harteveld ML, Garcia MB et al (2000) Radiotherapy for Graves’orbitopathy: randomised placebo controlled study. Lancet 355:1505–1509CrossRefPubMedGoogle Scholar
  10. 10.
    Minakarau N, Ezra DG (2013) Rituximab for thyroid-associated ophthalmopathy. Cochrane Database Syst Rev 5:CD009226Google Scholar
  11. 11.
    Sanyal P, Bing-You RG, Braverman LE (2008) Use of methotrexate to treat isolated Graves’ ophthalmopathy developing years after thyroidectomy and iodine 131 treatment of papillary thyroid cancer. Endocr Pract 14(4):422–425CrossRefPubMedGoogle Scholar
  12. 12.
    Bartalena L, Marcocci C, Tanda ML et al (2002) Orbital radiotherapy for Graves ophthalmopathy. Thyroid 12:245–250CrossRefPubMedGoogle Scholar
  13. 13.
    Prummel MF, Mourits MP, Blank L et al (1993) Randomized double-blind trial of prednisone versus radiotherapy in Graves’ ophthalmopathy. Lancet 342:949–954CrossRefPubMedGoogle Scholar
  14. 14.
    Smith JR, Rosenbaum JT (2001) A role of methotrexate in the management of non-infectious orbital inflammatory disease. Br J Ophthalmol 85:1220–1224CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Bartalena L, Tanda ML, Medea A et al (2002) Novel Approaches to the Management of Graves’ Ophtalmopathy. Hormones 1(2):76–90CrossRefPubMedGoogle Scholar
  16. 16.
    Strianese D, Piscopo R, Elefante A (2013) Unilateral proptosis in thyroid eye disease with subsequent contralateral involvement: retrospective follow-up study. BMC Ophthalmol 13:21CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Mourits MP, Prummel MF, Wiersinga WM et al (1997) Clinical activity score as a guide in the management of patients with Graves’ ophthalmopathy. Clin Endocrinol (Oxf). 47(1):9–14CrossRefPubMedGoogle Scholar
  18. 18.
    Pinchera A, Wiersinga W, Glinoer D et al (1992) Classification of eye changes of Graves’ disease. Thyroid 2(3):235–236CrossRefGoogle Scholar
  19. 19.
    Dolman PJ, Cahill K, Czyz CN et al (2012) Reliability of estimating ductions in thyroid eye disease an international thyroid eye disease society multicenter study. Ophthalmology 119(2):382–389. doi: 10.1016/j.ophtha.2011.07.011 (Epub 2011 Sep 29) CrossRefPubMedGoogle Scholar
  20. 20.
    Rundle FF (1945) Development and course of exophthalmos and ophthalmoplegia in Graves’ disease with special reference to the effect of thyroidectomy. Clin Sci 5:177–194PubMedGoogle Scholar
  21. 21.
    Bartalena L, Marcocci C, Pinchera A (1997) Treating severe Graves ophthalmopathy. Baillieres Clin Endocinol Metab 11:521–536CrossRefGoogle Scholar
  22. 22.
    Bartelena L, Marcocci C, Pinchera A (2002) Management of thyroid eye disease. Eur J Nucl Med Mol Imaging 29(Suppl 2):S458–S465 (Epub May 8) CrossRefGoogle Scholar
  23. 23.
    Bartalena L, Marcocci C, Bogazzi F et al (1991) Glucocorticoid therapy of Graves Ophthalmopathy. Exp. Clin Endocrinol 97:320–327CrossRefPubMedGoogle Scholar
  24. 24.
    Ohtsuka K, Sato A, Kawaguchi S et al (2003) Effect of steroid pulse therapy with and without orbital radiotherapy on Graves’ ophthalmopathy. Am J Ophthalmol 135:285–290CrossRefPubMedGoogle Scholar
  25. 25.
    Nagayama Y, Izumi M, Kiriyama T et al (1987) Treatment of Graves’ ophthalmopathy with high-dose intravenous methylprednisolone pulse herapy. Acta Endocrinol 116:513–518PubMedGoogle Scholar
  26. 26.
    Ohtsuka K, Sato A, Kawaguchi S et al (2002) Effect of high-dose intravenous steroid pulse therapy followed by three-month oral steroid therapy for Graves’ophthalmopathy. Jpn J Ophthalmol 46:563–567CrossRefPubMedGoogle Scholar
  27. 27.
    Le Moli R, Baldeschi L, Saeed P et al (2007) Determinants of liver damage associated with intravenous methylprednisolone pulse therapy in Graves’ ophthalmopathy. Thyroid 17(4):357–362CrossRefPubMedGoogle Scholar
  28. 28.
    Shams PN, Ma R, Pickles T et al (2014) Reduced risk of compressive optic neuropathy using orbital radiotherapy in patients with active thyroid eye disease. Am J Ophthalmol 157(6):1299–1305. doi: 10.1016/j.ajo.2014.02.044 (Epub 2014 Feb 26) CrossRefPubMedGoogle Scholar
  29. 29.
    Matthiensen C, Thompson JS, Thompson D et al (2012) The efficacy of radiation therapy in the treatment of Graves’ orbitopathy. Int J Radiat Oncol Biol Phys 82(1):117–123. doi: 10.1016/j.ijrobp.2010.08.053 (Epub 2010 Oct 27) CrossRefGoogle Scholar
  30. 30.
    Zygulska A (2009) Radiotherapy in the treatment of Graves ophthalmopathy-to do it or not? J Ocul Biol Dis Inf 3(1):1–11Google Scholar
  31. 31.
    Marcocci C, Bartalena L, Bruno-Bossio G et al (1993) Orbital radiotherapy in the treatment of endocrine ophthalmopathy: when and why? Endocrine ophthalmopathy. Molecular, immunological and clinical aspects. Dev Ophthalmol 25:131–141CrossRefPubMedGoogle Scholar
  32. 32.
    Smitt MC, Donaldson SS (1999) Radiation therapy for benign disease of the orbit. Sem Rad Oncol 9:179–189CrossRefGoogle Scholar
  33. 33.
    Wiersinga WM (2002) Retrobulbar irradiation in Graves orbitopathy: the Dutch experience. Ophthal Plast Reconstr Surg 18:175–176CrossRefPubMedGoogle Scholar
  34. 34.
    Gorman CA, Garrity JA, Fatourechi V, Bahn RS et al (2001) A prospective, randomized, double-blind, placebo-controlled study of orbital radiotherapy for Graves’ ophthalmopathy. Ophthalmology 108(9):1523–1534CrossRefPubMedGoogle Scholar
  35. 35.
    Wakelkamp IM, Tan H, Saeed P et al (2004) Orbital Irradiation for Graves’Ophthalmopathy Is It Safe? A Long-term Follow-up Study. Ophthalmology 111(8):1557–1562CrossRefPubMedGoogle Scholar
  36. 36.
    Marquez SD, Lum BL, McDougall IR et al (2001) Long-term results of irradiation for patients with progressive Graves’ ophthalmopathy. Int J Radiat Oncol Biol Phys 51(3):766–774CrossRefPubMedGoogle Scholar
  37. 37.
    Baldeschi L, MacAndie K, Koetsier E et al (2008) The influence of previous orbital irradiation on the outcome of rehabilitative decompression surgery in graves orbitopathy. Am J Ophthalmol 145:534–540CrossRefPubMedGoogle Scholar
  38. 38.
    Olivotto IA, Ludgate CM, Allen LH et al (1985) Supervoltage radiotherapy for Graves’ ophthalmopathy: CCABC technique and results. Int J Radiat Oncol Biol Phys 11(12):2085–2090CrossRefPubMedGoogle Scholar

Copyright information

© Royal Academy of Medicine in Ireland 2017

Authors and Affiliations

  • P. Grassi
    • 1
    Email author
  • D. Strianese
    • 1
  • R. Piscopo
    • 2
  • R. Pacelli
    • 3
  • G. Bonavolontà
    • 1
  1. 1.Department of Neuroscience, Odontostomatological and Reproductive SciencesUniversity “Federico II” of NaplesNaplesItaly
  2. 2.Department of OphthalmologyHumanitas Research HospitalMilanItaly
  3. 3.Department of Diagnostic Imaging and RadiotherapyUniversity “Federico II” of NaplesNaplesItaly

Personalised recommendations